Vol 31, No 2 (2024)
Original Article
Published online: 2022-06-15

open access

Page views 2121
Article views/downloads 642
Get Citation

Connect on Social Media

Connect on Social Media

High-density lipoprotein cholesterol to apolipoprotein A-1 ratio is an important indicator predicting in-hospital death in patients with acute coronary syndrome

Zhenjun Ji1, Guiren Liu2, Rui Zhang1, Abdlay Carvalho1, Jiaqi Guo1, Wenjie Zuo1, Xiaoguo Zhang1, Yangyang Qu1, Jie Lin3, Ziran Gu1, Yuyu Yao1, Genshan Ma1
Pubmed: 35762073
Cardiol J 2024;31(2):251-260.

Abstract

Background: Dyslipidemia plays a pivotal role in the pathogenesis of acute coronary syndrome (ACS). This study aims to investigate the value of two indices associated with lipid metabolism, low-density lipoprotein cholesterol to apolipoprotein B ratio (LBR) and high-density lipoprotein cholesterol to apolipoprotein A-1 ratio (HAR), to predict in-hospital death in patients with ACS. Methods: This single-center, retrospective, observational study included 3,366 consecutive ACS patients in Zhongda Hospital, Southeast University from July 2013 to January 2018. The clinical and laboratory data were extracted, and the in-hospital death and hospitalization days were also recorded. Results: All patients were equally divided into four groups according to quartiles of HAR: Q1 (HAR < 1.0283), Q2 (1.0283 ≤ HAR < 1.0860), Q3 (1.0860 ≤ HAR < 1.1798), and Q4 (HAR ≥ 1.1798). Overall, HAR was positively associated with the counts of neutrophils and monocytes, whereas negatively correlated to lymphocyte counts. HAR was negatively correlated to left ventricular ejection fraction (LVEF). Compared to other three groups, in-hospital mortality (vs. Q1, Q2, and Q3, p < 0.001) and hospitalization length (vs. Q1, Q2, and Q3, p < 0.001) were significantly higher in the Q4 group. When grouped by LBR, however, there was no significant difference in LVEF, in-hospital mortality, and hospitalization length among groups. After adjusting potential impact from age, systolic blood pressure, creatine, lactate dehydrogenase, albumin, glucose, and uric acid, multivariate analysis indicated that HAR was an independent factor predicting in-hospital death among ACS patients. Conclusions: HAR had good predictive value for patients’ in-hospital death after the occurrence of acute coronary events, but LBR was not related to in-hospital adverse events.

Article available in PDF format

View PDF Download PDF file

References

  1. Kimura K, Kimura T, Ishihara M, et al. Japanese Circulation Society Joint Working Group. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J. 2019; 83(5): 1085–1196.
  2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
  3. Claessen BE, Guedeney P, Gibson CM, et al. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc. 2020; 9(24): e018897.
  4. Youquan B. Biochemistry and molecular biology (2nd version). Science Press. 2020: 125–157.
  5. Ossoli A, Pavanello C, Calabresi L. High-density lipoprotein, lecithin: cholesterol acyltransferase, and atherosclerosis. Endocrinol Metab (Seoul). 2016; 31(2): 223–229.
  6. Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb. 2005; 12(2): 67–72.
  7. Kaneva AM, Potolitsyna NN, Bojko ER. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Arch Physiol Biochem. 2017; 123(1): 16–22.
  8. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005; 25(3): 553–559.
  9. Krauss RM. Small dense low-density lipoprotein particles: clinically relevant? Curr Opin Lipidol. 2022 [Epub ahead of print].
  10. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3): 267–270.
  11. Xiao J, Borné Y, Bao X, et al. Comparisons of risk factors for abdominal aortic aneurysm and coronary heart disease: a prospective cohort study. Angiology. 2021; 72(1): 24–31.
  12. Chyu KY, Shah PK. HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Front Pharmacol. 2015; 6: 187.
  13. Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol. 2018; 3(9): 806–814.
  14. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010; 55(24): 2727–2735.
  15. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995; 96(6): 2758–2767.
  16. Fernandes das Neves M, Batuca JR, Delgado Alves J. The role of high-density lipoprotein in the regulation of the immune response: implications for atherosclerosis and autoimmunity. Immunology. 2021; 164(2): 231–241.
  17. Rhee EJ, Byrne CD, Sung KC. The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2017; 24(2): 148–153.
  18. Emergency Medical Branch of Chinese Medical Doctor Association, Emergency and First Aid Branch of the China Medical Care International Exchange Promotion Association. Emergency rapid diagnosis and treatment guidelines for acute coronary syndrome. Chin J Emerg Med. 2019; 28: 421–428.
  19. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001; 104(10): 1108–1113.
  20. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22): 2089–2099.
  21. Ito F, Ito T. High-density lipoprotein (HDL) triglyceride and oxidized HDL: new lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease. Antioxidants (Basel). 2020; 9(5).
  22. Sung KC, Ryu S, Wild SH, et al. An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart. 2015; 101(7): 553–558.
  23. Prats-Uribe A, Sayols-Baixeras S, Fernández-Sanlés A, et al. High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study. Metabolism. 2020; 112: 154351.
  24. Mani P, Uno K, St John J, et al. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients. Am J Cardiol. 2014; 114(5): 681–685.
  25. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008; 51(6): 634–642.
  26. Tani S, Saito Y, Anazawa T, et al. Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study. Int Heart J. 2011; 52(6): 343–347.
  27. Rabizadeh S, Rajab A, Mechanick JI, et al. LDL/apo B ratio predict coronary heart disease in type 2 diabetes independent of ASCVD risk score: a case-cohort study. Nutr Metab Cardiovasc Dis. 2021; 31(5): 1477–1485.
  28. Tani S, Yagi T, Atsumi W, et al. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017; 16(1): 123.
  29. Drexel H, Larcher B, Mader A, et al. The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis. 2021; 329: 44–49.